Losartan

Limits on what this shows

• Key negative or null findings: No study, human or animal, reporting a losartan-associated reduction in mitochondrial content, membrane potential, or respiratory capacity was found. A mechanistically adjacent olmesartan (not losartan) study in mouse skeletal muscle found that AT1-receptor blockade only partially reversed angiotensin II-induced mitochondrial content loss in vivo, and did not reverse it at all in cultured myotubes, where AT2-receptor blockade was the effective arm (see the ATP production entry below); this tempers any assumption that AT1 blockade is reliably mitochondria-protective across tissues.
• At-risk subgroups: None identified; the only directional human evidence favors older, prefrail adults, not a risk subgroup.

Regulatory status

Not addressed in the FDA label. Mitochondrial function is not a monitored parameter for losartan.

Population evidence

A randomized, placebo-controlled pilot trial in prefrail older adults (25 completers of 37 enrolled; 10 losartan escalated from 25 to 100 mg over 6 months, 15 placebo, ages 70-90) reported that losartan was associated with an estimated 89% lower odds of frailty at study end (P=.03), with none of the losartan-arm completers classified as frail versus 27% of the placebo arm. Companion metabolomic findings in the same trial included increased arginine and spermidine (an autophagy/mitophagy-associated marker), decreased nitrotyrosine (an oxidative-damage marker, also relevant to the oxidative-stress entry below), and lower accumulation of extramitochondrial TCA-cycle metabolites, which the authors interpreted as better mitochondrial substrate utilization (Casanova AG et al., J Gerontol A Biol Sci Med Sci 2022;77(12):2356). This is Tier A (human, losartan-specific) but a single small pilot.

Mechanism

No mitochondrial-toxicity mechanism (class E) is described for losartan anywhere in the literature searched. The pilot trial's authors propose the improvement may run partly through PPAR-gamma signaling rather than through AT1-receptor blockade alone, meaning even the protective signal may not be a class-wide ARB effect.

Counter-evidence held on record

The pilot trial is small (10 losartan completers), was not designed with mitochondrial burden as its primary endpoint, and its authors themselves float a non-AT1 mechanism (PPAR-gamma) for the benefit, meaning it cannot be read as confirming a losartan/AT1-blockade-specific mitochondrial-protection mechanism, only as failing to show any burden. No consumer claim asserting losartan harms mitochondria was found to rebut (see the claim audit below). This must never be surfaced as evidence that losartan depletes mitochondrial function or as grounds for a mitochondrial-support supplement recommendation. If surfaced at all, it should read as a no-burden-found finding with a preliminary, small-trial signal toward benefit, explicitly labeled as the drug's own pharmacology under investigation, not a nutrient-status claim.

Limits on what this shows

• Key negative or null findings: The Am J Cardiol crossover trial found no significant improvement in flow-mediated dilation despite the inflammatory-marker reduction, showing the protective signal does not uniformly extend to every vascular-function endpoint tested.
• At-risk subgroups: None identified.

Regulatory status

Not addressed in the FDA label. Oxidative-stress markers are not a monitored parameter for losartan.

Population evidence

The same pilot trial cited under mitochondrial burden reported decreased nitrotyrosine, a marker of protein oxidative damage, in the losartan arm (Casanova AG et al., J Gerontol A Biol Sci Med Sci 2022;77(12):2356). A separate randomized, double-blind, placebo-controlled crossover trial in 18 healthy older adults (mean age 75; losartan 50 mg/day for 6 weeks vs placebo, 2-week washout) found losartan reduced circulating vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1, though it did not significantly change flow-mediated dilation (a study of aging-related endothelial impairment, Am J Cardiol 2002;89 [PMID 11867042]). A randomized crossover study in patients with hypertension and type 2 diabetes reported that losartan and lercanidipine both attenuated LDL oxidation (Rachmani R et al., Clin Pharmacol Ther 2002); this last source's full text and exact effect sizes could not be independently opened this session and are not asserted beyond the direction reported in its title and indexing.

Mechanism

No mechanism by which losartan increases oxidative stress (class E) is described anywhere in the literature searched. The consistent direction across three independent losartan-specific human studies is toward reduced oxidative and inflammatory markers, plausibly via reduced angiotensin II-driven NADPH oxidase activity, which is losartan's own intended vascular pharmacology, not an inadvertent nutrient-status effect (Hard Rule 1).

Counter-evidence held on record

All three supporting studies are small (n=25, n=18, and an unconfirmed crossover n), none was designed with oxidative stress as its sole primary endpoint, and two of the three could not be independently opened in full text this session. No consumer claim asserting losartan increases oxidative stress was found to rebut. This must never be surfaced as evidence that losartan depletes antioxidant capacity or as grounds for an antioxidant-supplement recommendation. The direction of every losartan-specific finding located is protective; if surfaced, it should read as a no-burden-found finding, not a deficiency risk.

Limits on what this shows

• Key negative or null findings: Losartan is a small minority (0.8%) of all reported ARB sprue-like enteropathy cases, and no case series or cohort study specifically measuring iron status (ferritin, transferrin saturation, or serum iron) in losartan-associated enteropathy was found. A drug-interaction checker found no absorption interaction between oral iron supplements and losartan in the other direction (Drugs.com, Fer-Iron and losartan, cited below).
• At-risk subgroups: Patients with unexplained chronic diarrhea, weight loss, or villous atrophy on ARB therapy generally, and losartan specifically only very rarely; median time to symptom onset across the ARB class ranged from 2 weeks to 13 years of use in the systematic review, so duration of use does not reliably predict risk.

Regulatory status

The FDA added a boxed warning about sprue-like enteropathy to olmesartan's label in 2013; losartan's label carries no equivalent warning.

Population evidence

A systematic review of ARB-associated sprue-like enteropathy identified 248 cases: olmesartan 233 (94.0%), telmisartan 5 (2.0%), irbesartan 4 (1.6%), valsartan 3 (1.2%), losartan 2 (0.8%), eprosartan 1 (0.4%). Across all agents, villous atrophy was reported in 92.2% of 218 histologically assessed cases, celiac serology was negative in 98.8% of 169 tested, and 97.4% of 239 cases resolved completely after stopping the implicated ARB (Angiotensin II receptor blockers and gastrointestinal adverse events resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep 2019;7(3):162). The review did not separately report anemia or iron-deficiency rates. A losartan-specific case (61-year-old woman, 3 years of losartan use, 3-month history of abdominal pain and diarrhea, isolated ileal villous atrophy on biopsy with a normal duodenum) documented vitamin B12 deficiency and complete clinical resolution after losartan was stopped and replaced with amlodipine; iron studies were not reported in the accessible abstract (Losartan-induced sprue-like enteropathy presenting with isolated ileal villous atrophy: a report of a rare and atypical case. Cureus 2025).

Mechanism

Mechanism class A (absorption interference via mucosal injury): ARB-associated villous atrophy reduces the small-bowel absorptive surface. Because the verified losartan case showed isolated ileal involvement with a normal duodenum, and iron absorption occurs predominantly in the duodenum and proximal jejunum while B12 absorption is a terminal-ileum function, the anatomic pattern in this specific case explains the documented B12 deficiency rather than an iron one; a more proximal (duodenal/jejunal) pattern of injury, as more typically described for olmesartan, would be the pattern expected to threaten iron absorption instead.

Counter-evidence held on record

Hard Rule 2 applies directly here: the documented deficiency in the one losartan case opened in full was B12, not iron, and anemia (where reported elsewhere in the ARB enteropathy literature) is not itself proof of iron deficiency unless iron studies were actually measured. This entry does not assert losartan causes iron-deficiency anemia; it reports a mechanism (rare, class-level, occasionally losartan-specific malabsorption) that could plausibly affect iron if the anatomic pattern of injury were more proximal than the one case documented shows. Must not be presented as “losartan depletes iron.” If surfaced, it should be framed as a rare gastrointestinal adverse-effect mechanism, overwhelmingly associated with a different ARB (olmesartan), that warrants medical evaluation of unexplained chronic diarrhea or weight loss, not as a reason to monitor or supplement iron in an otherwise well patient.

Limits on what this shows

• Why no grade: A single paper titled Losartan and its interaction with copper(II): biological effects (J Inorg Biochem 2007; PMID 17651974) was located, but its full text could not be opened this session (repeated 429/403 responses; see Sources), so it is not possible to confirm whether it addresses human or animal copper nutritional status, coordination chemistry unrelated to biology (a common subject for that journal), or something else entirely. Absent a verified Tier B or C finding, and absent any circulating consumer claim naming copper for losartan or the ARB class, neither a yellow nor a white grade is supported. This is the one category in the 2026-09-10 expansion where the evidence search came up genuinely empty rather than merely low-tier.
• What would fill this tier: Independently opened full text of the J Inorg Biochem 2007 paper confirming a biological (not purely chemical) copper interaction; any animal or in vitro study of ARB exposure and intestinal or cellular copper transport; any human ARB-class trial reporting serum copper or ceruloplasmin as an endpoint; or a circulating consumer claim naming losartan or ARBs and copper, which would at minimum support a white-tier rebuttal entry.

Counter-evidence held on record

A drug-interaction checker found no interaction between losartan and zinc, and did not list copper at all in connection with losartan, other than an unrelated note about trace-metal malabsorption in gastrointestinal disease generally (Drugs.com, losartan with Zinc, cited below). This confirms the absence of a documented reverse-direction interaction but does not itself establish or rule out a forward-direction copper-status effect. Must not be presented as reassurance that losartan is safe for copper status; it is an unresolved gap in the evidence, not a tested and cleared claim. No supplementation guidance follows from an ungraded entry either way.

Limits on what this shows

• Key negative or null findings: A separate rat study found gut microbiota composition instead altered losartan's own pharmacokinetics: intestinal flora from spontaneously hypertensive rats degraded losartan more than flora from normotensive controls, and inducing dysbiosis with ceftriaxone cut losartan's area-under-curve by roughly half in vivo, with Enterococcus faecalis identified as directly metabolizing losartan to E-3179 (Effects of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in rats. Front Microbiol 2025). This is a reverse-direction interaction, the microbiome affecting the drug, not the drug affecting the microbiome or a nutrient, and per Hard Rule 4 is recorded here as context, not folded into the risk grade above.
• At-risk subgroups: None identified for a losartan-specific microbiome risk. Confounding by indication (Hard Rule 2) is a live, unresolved concern: hypertension itself is independently associated with gut dysbiosis, so any “normalization” observed during losartan treatment in these animal models may track blood-pressure control generally rather than a losartan-specific gut mechanism.

Regulatory status

Not addressed in the FDA label; the gut microbiome is not a monitored parameter for losartan.

Population evidence

A 2025 systematic review of ACE inhibitors and ARBs and the gut microbiome identified 9 eligible studies overall: 8 in rodent models and only 1 in humans. Three of the animal studies used losartan specifically; across them, losartan increased microbial diversity, decreased the Firmicutes/Bacteroidetes ratio, expanded short-chain-fatty-acid-producing bacteria, improved gut barrier integrity (increased tight-junction proteins), and reduced inflammatory markers including endotoxin, IL-6, and TNF-alpha; fecal microbiota transplantation from losartan-treated donor rats also lowered blood pressure in recipients. The review states human data are limited and the single human study carried a moderate risk of bias (Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review. Front Endocrinol 2025). One of the three losartan-specific rodent studies was independently opened: in spontaneously hypertensive rats given losartan 20 mg/kg/day for 12 weeks (n=6/group) versus vehicle, atorvastatin, or aspirin, losartan significantly increased microbial diversity and richness (P<.01), reversed the hypertension-associated rise in the Firmicutes/Bacteroidetes ratio, increased Alistipes, Bacteroides, Butyricimonas, Bifidobacterium, and acetate/butyrate producers, and decreased lactate-producing bacteria (P<.01 for both), while atorvastatin and aspirin produced no significant microbiome change (Effects of Losartan, Atorvastatin, and Aspirin on Blood Pressure and Gut Microbiota in Spontaneously Hypertensive Rats. Molecules 2023;28(2):612). The single human study identified by the systematic review (55 hypertensive patients, Beijing, generic “ACEI/ARB therapy” without naming individual drugs) reported reduced potentially pathogenic Enterobacter and Klebsiella and increased beneficial Odoribacter in treated patients, with no significant difference in overall diversity, but did not identify which patients were on losartan specifically and had no normotensive control group (Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients. Front Cell Dev Biol 2022).

Mechanism

No microbiome-disruption mechanism (class G) is described for losartan anywhere in the literature searched. The proposed mechanism runs the opposite direction: reduced angiotensin II signaling in the gut wall is hypothesized to improve barrier integrity and reduce a hypertension-associated dysbiosis, contributing to (not resulting from) losartan's blood-pressure-lowering effect.

Counter-evidence held on record

Every losartan-specific finding located is rodent-derived (Tier B) and protective in direction; the single human study is Tier C for losartan (drug not specified) and rated moderate risk of bias by its own systematic review. No study, human or animal, reporting losartan causing new or worsened dysbiosis was found. No consumer claim asserting losartan harms the gut microbiome was found to rebut. Must not be surfaced as “losartan disrupts your gut bacteria” or as grounds for a probiotic recommendation. If surfaced, it should read as a no-risk-found context flag, noting the animal evidence trends toward normalization of hypertension-associated dysbiosis rather than harm, and that confounding by the underlying hypertension has not been excluded.

Limits on what this shows

• Key negative or null findings: In the RENAAL sub-analysis, the hemoglobin-lowering effect did not cancel out losartan's renoprotective benefit, which held across the hemoglobin range studied. The COPD/erythrocytosis and transplant reports describe the effect as a therapeutic correction of pre-existing excess erythrocytosis rather than an unwanted drop into anemia in patients who started with normal counts; a separate case report titled Anemia Due to Losartan in Hypertensive Renal Transplant Recipients Without Posttransplant Erythrocytosis (PMID 15964363, cited below; authors not independently confirmed this session) suggests the effect is not perfectly confined to the erythrocytosis subgroup, but this is case-report-level evidence, not a cohort finding.
• At-risk subgroups: Renal transplant recipients with post-transplant erythrocytosis, patients with COPD-associated secondary erythrocytosis, and patients with diabetic nephropathy and RAAS blockade generally; the effect is bounded toward patients with an elevated or high-normal baseline hematocrit rather than the general hypertensive population.

Regulatory status

Not addressed as a monitoring requirement in the FDA label. The hematocrit-lowering effect is documented in the transplant, pulmonary, and diabetic-nephrology literature rather than the label itself, and losartan has been studied and used off-label specifically to treat post-transplant and secondary erythrocytosis.

Population evidence

Four independent losartan-specific human reports converge on the same direction across three populations. In renal transplant recipients with post-transplant erythrocytosis, losartan lowered hematocrit (J Am Soc Nephrol 1998; PMID not independently confirmed this session, see Sources) and, in a separate comparative study against enalapril, reduced hemoglobin alongside falls in circulating erythropoietin and insulin-like growth factor-1 (Am J Kidney Dis 2002; PMID 11877580). Both are attributed in indexing to the same Vlahakos/Marathias research group responsible for the confirmed Ann Intern Med paper below, but that attribution was not independently verified against the primary text this session. In patients with COPD and secondary erythrocytosis, a research letter from the same group reported losartan reduced hematocrit (Vlahakos DV, Marathias KP, Kosmas EN. Ann Intern Med 2001;134(5):426-427). In the RENAAL trial cohort already described above for potassium (n=1,513, placebo-controlled, type 2 diabetic nephropathy, 3.4-year mean follow-up), losartan was separately associated with a significant decrease in hemoglobin concentration, and this renoprotective benefit was maintained despite the lower hemoglobin, including in patients who started with low hemoglobin (Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD. Kidney Int 2008;73(5):630-636).

Mechanism

RAAS mechanism class F (hormonal disturbance), the same axis as the potassium entry: angiotensin II normally stimulates renal and possibly hepatic erythropoietin production; AT1-receptor blockade blunts this stimulus, lowering circulating erythropoietin and, downstream, hemoglobin/hematocrit. This is not a mineral- or vitamin-deficiency mechanism.

Counter-evidence held on record

None of the four primary reports behind this entry could be opened in full text this session (see Sources); the population, design, and direction are drawn from their indexed titles and abstracts, and the RENAAL hemoglobin figures (n=1,513, mean follow-up, direction of effect) are drawn from a verified institutional-repository abstract rather than the full journal article. No specific effect size or confidence interval from any of the four is asserted here beyond what that abstract states. This is a known hormonal mechanism of RAAS blockade rather than a novel discovery, and losartan is not unique among ARBs in this respect; class-level extrapolation was not needed because losartan itself has been directly studied in all four reports. This is a hormonal/hemodynamic effect on oxygen-carrying capacity, not a nutrient deficiency, and iron status is not the mechanism. The consumer-facing copy must never suggest iron supplementation in response to this entry, must not conflate it with the separate, much rarer iron entry below, and should note that in the populations studied the hematocrit reduction is often the intended clinical effect rather than an adverse one.

Limits on what this shows

• Key negative or null findings: Cellular ATP content was explicitly unchanged by angiotensin II despite measurable mitochondrial content and enzyme-activity changes, meaning even the class-level evidence does not show a clean ATP-output effect. The pilot losartan trial cited under mitochondrial burden reported lower accumulation of extramitochondrial TCA-cycle metabolites in the losartan arm, which its authors read as better substrate utilization, but this is an indirect metabolomic marker, not a direct ATP measurement, and is the same evidence already counted under mitochondrial burden (see the overlap map below).
• At-risk subgroups: None identified; no losartan-specific human or animal ATP data exists to define one.

Regulatory status

Not addressed in the FDA label; ATP production is not a measurable clinical parameter and is not monitored for any antihypertensive.

Population evidence

No human or animal study measuring ATP synthesis, ATP content, or oxidative phosphorylation capacity with losartan specifically in the cohort was found. The nearest mechanistic study used chronic angiotensin II infusion in C57BL/6 mice and cultured C2C12 myotubes, with olmesartan (RNH6270/CS-866), not losartan, as the AT1-receptor blocker and PD123319 as the AT2-receptor blocker. Angiotensin II reduced mitochondrial DNA copy number (22% reduction at 10^-6 mol/L in vitro, n=12, P<.01) and reduced activity of the mitochondrial enzymes COX and beta-HAD, but cellular ATP content itself showed no significant change. In cultured cells, AT2-receptor blockade fully reversed the mitochondrial content loss while AT1-receptor blockade did not; in mice, both AT1- and AT2-receptor blockade only partially reversed it (Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes 2009;58(3):710). This is Tier C for losartan (a different ARB was the AT1 blocker tested) and directionally mixed even for the class.

Mechanism

Two proposed pathways for angiotensin II reducing muscle mitochondrial content: AT2-receptor-dependent suppression of mitochondrial biogenesis (PGC1-alpha/Tfam downregulation) and AT1-receptor-dependent acceleration of mitochondrial degradation via reactive oxygen species. Because losartan blocks AT1, not AT2, this mechanism predicts losartan might reduce mitophagy-driven mitochondrial loss but would not address the AT2-mediated biogenesis pathway, consistent with the partial, not complete, reversal seen with AT1 blockade in this olmesartan-based model.

Counter-evidence held on record

The only mechanistic study located tested a different ARB, found AT1 blockade only partially or not at all protective depending on the tissue compartment, and found ATP content itself unmoved by the angiotensin II exposure it did test. This is weak, mixed, class-level evidence, not a losartan-specific finding in either direction, and Hard Rule 1 applies: no known losartan mechanism of action or adverse effect directly targets ATP synthesis. Must not be surfaced as “losartan lowers your cellular energy production.” The evidence is indirect, drawn from a different ARB, and even that evidence shows no change in ATP content itself. No supplement or CoQ10-style energy-support claim is supported by this entry; see the existing CoQ10 rebuttal below, which this entry does not reopen or strengthen.